Please login to the form below

Not currently logged in
Email:
Password:

Alkopharma acquires rights to Navoban

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights.

Novartis has closed a deal to sell its antiemetic drug, Navoban, to fellow Swiss company, Alkopharma, giving Alkopharma worldwide rights. 

Alkopharma intends to commercialise the drug in more than 80 countries and will drive into new markets, such as the US, to reinforce the company's growing position globally.

Alain Bouaziz, Alkopharma's president and CEO, said the deal marked an exciting step for the company and maintained the ethical basis that the company was founded on 10 years ago.

Alkopharma acquires original molecules from large pharmaceutical companies that are no longer interested in manufacturing drugs from them, such as those used in orphan diseases. In this way, it attempts to meet patients' needs for personalised treatments for rare diseases.

A new manufacturing facility is to be built in Wallis, Switzerland, starting in January 2010, to support the company's R&D and expansion plans. It will house two units, one dedicated to the production of anti-tumour products and the other to biotech-derived products.

11th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics